Cargando…

Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant

BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) in the common marmoset monkey (Callithrix jacchus) is a relevant preclinical model for translational research into immunopathogenic mechanisms operating in multiple sclerosis (MS). Prior studies showed a core pathogenic role of T and B cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagessar, S. Anwar, Heijmans, Nicole, Blezer, Erwin L A, Bauer, Jan, Weissert, Robert, ‘t Hart, Bert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574133/
https://www.ncbi.nlm.nih.gov/pubmed/26377397
http://dx.doi.org/10.1186/s12974-015-0378-5
_version_ 1782390575674163200
author Jagessar, S. Anwar
Heijmans, Nicole
Blezer, Erwin L A
Bauer, Jan
Weissert, Robert
‘t Hart, Bert A.
author_facet Jagessar, S. Anwar
Heijmans, Nicole
Blezer, Erwin L A
Bauer, Jan
Weissert, Robert
‘t Hart, Bert A.
author_sort Jagessar, S. Anwar
collection PubMed
description BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) in the common marmoset monkey (Callithrix jacchus) is a relevant preclinical model for translational research into immunopathogenic mechanisms operating in multiple sclerosis (MS). Prior studies showed a core pathogenic role of T and B cells specific for myelin oligodendrocyte glycoprotein (MOG). However, in those studies, the quality of the response against MOG epitopes was strongly biased by bacterial antigens in the complete Freund’s adjuvant (CFA), in which the immunizing recombinant human (rh) MOG protein had been formulated. In response to the need of a more refined EAE model, we have tested whether disease could also be induced with rhMOG in incomplete Freund’s adjuvant (IFA). METHOD: Marmosets were immunized with rhMOG emulsified in IFA in the dorsal skin. Monkeys that did not develop neurological deficit were given booster immunizations at 28-day interval with the same antigen preparation. In a second experiment, three marmoset twin pairs were sensitized against MOG peptides in IFA to study a possibility for suppressive activity towards pathogenic T cells directed against the encephalitogenic epitope MOG40-48. RESULTS: Despite the absence of strong danger signals in the rhMOG/IFA inoculum, all monkeys developed clinically evident EAE symptoms. Moreover, in all monkeys, demyelinated lesions were present in the white matter and in two cases also in the cortical grey matter. Immune profiling at height of the disease showed a dominant T cell response against the overlapping peptides 14–36 and 24–46, but reactivity against the pathogenically most relevant peptide 34–56 was conspicuously absent. In the second experiment, there was an indication for a possible suppressive mechanism. CONCLUSIONS: Immunization of marmoset monkeys with rhMOG in IFA elicits clinical EAE in all animals. Moreover, rhMOG contains pathogenic and regulatory epitopes, but the pathogenic hierarchy of rhMOG epitopes is strongly influenced by the adjuvant in which the protein is formulated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12974-015-0378-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4574133
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45741332015-09-19 Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant Jagessar, S. Anwar Heijmans, Nicole Blezer, Erwin L A Bauer, Jan Weissert, Robert ‘t Hart, Bert A. J Neuroinflammation Research BACKGROUND: Experimental autoimmune encephalomyelitis (EAE) in the common marmoset monkey (Callithrix jacchus) is a relevant preclinical model for translational research into immunopathogenic mechanisms operating in multiple sclerosis (MS). Prior studies showed a core pathogenic role of T and B cells specific for myelin oligodendrocyte glycoprotein (MOG). However, in those studies, the quality of the response against MOG epitopes was strongly biased by bacterial antigens in the complete Freund’s adjuvant (CFA), in which the immunizing recombinant human (rh) MOG protein had been formulated. In response to the need of a more refined EAE model, we have tested whether disease could also be induced with rhMOG in incomplete Freund’s adjuvant (IFA). METHOD: Marmosets were immunized with rhMOG emulsified in IFA in the dorsal skin. Monkeys that did not develop neurological deficit were given booster immunizations at 28-day interval with the same antigen preparation. In a second experiment, three marmoset twin pairs were sensitized against MOG peptides in IFA to study a possibility for suppressive activity towards pathogenic T cells directed against the encephalitogenic epitope MOG40-48. RESULTS: Despite the absence of strong danger signals in the rhMOG/IFA inoculum, all monkeys developed clinically evident EAE symptoms. Moreover, in all monkeys, demyelinated lesions were present in the white matter and in two cases also in the cortical grey matter. Immune profiling at height of the disease showed a dominant T cell response against the overlapping peptides 14–36 and 24–46, but reactivity against the pathogenically most relevant peptide 34–56 was conspicuously absent. In the second experiment, there was an indication for a possible suppressive mechanism. CONCLUSIONS: Immunization of marmoset monkeys with rhMOG in IFA elicits clinical EAE in all animals. Moreover, rhMOG contains pathogenic and regulatory epitopes, but the pathogenic hierarchy of rhMOG epitopes is strongly influenced by the adjuvant in which the protein is formulated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12974-015-0378-5) contains supplementary material, which is available to authorized users. BioMed Central 2015-09-17 /pmc/articles/PMC4574133/ /pubmed/26377397 http://dx.doi.org/10.1186/s12974-015-0378-5 Text en © Jagessar et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Jagessar, S. Anwar
Heijmans, Nicole
Blezer, Erwin L A
Bauer, Jan
Weissert, Robert
‘t Hart, Bert A.
Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant
title Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant
title_full Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant
title_fullStr Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant
title_full_unstemmed Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant
title_short Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant
title_sort immune profile of an atypical eae model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete freund’s adjuvant
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574133/
https://www.ncbi.nlm.nih.gov/pubmed/26377397
http://dx.doi.org/10.1186/s12974-015-0378-5
work_keys_str_mv AT jagessarsanwar immuneprofileofanatypicaleaemodelinmarmosetmonkeysimmunizedwithrecombinanthumanmyelinoligodendrocyteglycoproteininincompletefreundsadjuvant
AT heijmansnicole immuneprofileofanatypicaleaemodelinmarmosetmonkeysimmunizedwithrecombinanthumanmyelinoligodendrocyteglycoproteininincompletefreundsadjuvant
AT blezererwinla immuneprofileofanatypicaleaemodelinmarmosetmonkeysimmunizedwithrecombinanthumanmyelinoligodendrocyteglycoproteininincompletefreundsadjuvant
AT bauerjan immuneprofileofanatypicaleaemodelinmarmosetmonkeysimmunizedwithrecombinanthumanmyelinoligodendrocyteglycoproteininincompletefreundsadjuvant
AT weissertrobert immuneprofileofanatypicaleaemodelinmarmosetmonkeysimmunizedwithrecombinanthumanmyelinoligodendrocyteglycoproteininincompletefreundsadjuvant
AT thartberta immuneprofileofanatypicaleaemodelinmarmosetmonkeysimmunizedwithrecombinanthumanmyelinoligodendrocyteglycoproteininincompletefreundsadjuvant